Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBloomsbury Share News (BMY)

Share Price Information for Bloomsbury (BMY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 536.00
Bid: 536.00
Ask: 546.00
Change: -4.00 (-0.74%)
Spread: 10.00 (1.866%)
Open: 550.00
High: 550.00
Low: 536.00
Prev. Close: 540.00
BMY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Decent morning for Footsie

Tue, 18th May 2010 12:10

Footsie has made decent progress this morning helped by gains for utilities and the non-bank and insurance bits of the finance sector. Man Group is the best performer on reflection of yesterday's deal to buy GLG for $1.6bn. Inter-dealer broker ICAP is also in demand, while mezzanine finance lender Intermediate Capital is also showing well.In today's company news, mobile giant Vodafone expects to see revenues in its core business grow again in the current year despite problems in India, where it took a £2.3bn impairment hit after intense competition. Underlying profits were £11.5bn accompanied by a promise of a 7% annual dividend increase for the next three years. British Land had a "good" year despite the challenging and volatile markets, lifting net asset value (NAV) by 27%, more than many analysts had predicted. The real estate giant revealed net asset value per share at 31 March 2010 was 504p, while the portfolio valuation grew 13.5%.AstraZeneca has signed a deal with Teva Pharmaceuticals USA to settle patent litigation regarding Teva's proposed generic version of Astra's Entocort EC (budesonide) capsules used to treat Crohn's disease. The Anglo-Swedish drug giant has granted Teva a license to enter the US market with its generic version of oral budesonide on 15 February 2012, subject to regulatory approval, or earlier in certain circumstances.Directories group Yell has announced the departure of its chief executive and chief financial officer at the same time as unveiling a move into profit. Chief executive John Condron and chief financial officer John Davis are to step down. Condron will retire by May 2011, while Davis will leave the company once a successor is in place.The underlying improvement in revenues and margins at medical and engineering group Smiths continued in the three months to end April. "Smiths Group delivered margin improvement and strong cash generation through its programme of operational improvement in the nine months to 1 May 2010," it added.North Sea oil group Enquest is also in demand after yesterday's trading update was largely overlooked. Milk and cheese producer Dairy Crest served up a 5% increase in adjusted annual pre-tax profit, posted a 19% reduction in year end net debt and said trading at the start of the new year is in line with company expectations. The group, whose key brands include Cathedral City, Country Life and Clover, said adjusted pre-tax profit rose to £83.5m for the year ended 31 March 2010 from £79.5m the same time a year earlier.A pre-AGM statement from serviced office group Regus has smacked its share price. "Trading conditions remain tough which is likely to impact our pace of recovery. The UK remains our most difficult region and the early signs of improvement seen in the first quarter have lost some momentum in a fragile market," it said.Telecoms hardware group BATM crashed as it warned it will only break-even this half due to a slow-down in orders from its major OEM customer.
More News
26 Mar 2018 21:56

Reuters Health News Summary

Following is a summary of current health news briefs. Biohaven plunges as investors pit migraine data against Allergan's drug Biohaven Pharmaceutical Holding said its acute two a

Read more
26 Mar 2018 13:56

Reuters Health News Summary

Following is a summary of current health news briefs. Singapore pharma on recovery path after worst output in decades Singapore's among

Read more
26 Mar 2018 13:56

Reuters Health News Summary

Following is a summary of current health news briefs. Singapore pharma on recovery path after worst output in decades Singapore's among

Read more
26 Mar 2018 07:23

UPDATE 1-Roche's Tecentriq cocktail notches another lung cancer success

ZURICH, March 26 (Reuters) - Roche's immunotherapy Tecentriq combined with other drugs boosted lung cancer patients' survival versus an older cocktail, the Swiss trial

Read more
25 Mar 2018 14:15

Israel to launch Big Data health project

By Maayan Lubell JERUSALEM, March 25 (Reuters) - Israel will invest nearly 1 billion shekels ($287 million) in a to a

Read more
20 Mar 2018 07:05

UPDATE 1-Roche says Tecentriq, chemo cut risk of death in type of lung cancer

ZURICH, March 20 (Reuters) - Roche's immunotherapy Tecentriq plus chemotherapy cut the risk of disease worsening or death in advanced squamous lung cancer, but it did not

Read more
19 Mar 2018 17:59

Bloomsbury Publishing Expecting Profitability To Beat Expectations

LONDON (Alliance News) - Bloomsbury Publishing PLC said on Monday it expects its full-year profit and revenue to both be ahead of expectations.For the year ending 28 to

Read more
20 Jan 2017 09:08

Bloomsbury Publishing Says Chairman Salz To Step Down In July

Read more
27 Oct 2016 07:43

Bloomsbury Publishing Sees Stronger Second Half As Trading In Line

Read more
13 Jul 2016 12:55

Bloomsbury Publishing plots expansion into B2B market

(ShareCast News) - Harry Potter publisher Bloomsbury Publishing held a capital markets day for investors and analysts on Wednesday to present plans to enter the business-to-business market, while also confirming first-quarter trading remained in line with full year expectations. Bloomsbury unveiled

Read more
13 Jul 2016 08:20

Bloomsbury Publishing Says Full Year Trading To Meet Expectations

Read more
12 Jul 2016 15:11

UK Shareholder Meetings Calendar - Next 7 Days

Read more
8 Jul 2016 15:00

UK Shareholder Meetings Calendar - Next 7 Days

Read more
19 May 2016 12:43

Bloomsbury moves towards digital B2B after strong FY

(ShareCast News) - Bloomsbury, the publisher behind the Harry Potter phenomenon, has turned in an overall strong set of full-year results and launched a 2020 strategy to move into digital B2B publishing. It booked a full-year pretax profit of £10.36m, from a year-earlier profit of £9.60m, with reven

Read more
19 May 2016 08:18

Bloomsbury To Reoganise Divisions As Profit Lifted By Children's Books

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.